B&W nets $9M for Mo-99 production using low-enriched uranium
Babcock & Wilcox Technical Services Group (B&W TSG) has been awarded $9 million from the National Nuclear Security Administration (NNSA) for further development of reactor technology for medical isotope production using low-enriched uranium.

B&W TSG and Covidien are developing technology for the manufacture of molybdenum-99 (Mo-99) and the program has the potential to supply more than 50 percent of U.S. demand for Mo-99, said B&W TSG, based in Lynchburg, Va.

Recently, NNSA also selected GE Hitachi Nuclear Energy to create a reliable U.S. supply of Mo-99 without the use of highly enriched uranium to overcome the isotope shortage.